Skip to main content

Table 1 Background factors at the time of liver biopsy

From: Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease

n

446

Age

52 (18–87)

Sex, male/female

268/178

Body mass index (kg/m2)

26.3 (18.1–42.4)

History of liver cancer, yes/no

29/416

History of non-liver malignancy, yes/no

39/405

Type 2 diabetes mellitus, yes/no

147/297

Dyslipidemia, yes/no

151/294

Hypertension, yes/no

200/246

Hyperuricemia, yes/no

46/399

Smoking, yes/no

98/338

Albumin (g/dL)

4.1 (2.8–6.9)

Aspartate aminotransferase (IU/L)

44 (12–378)

Alanine aminotransferase (IU/L)

69 (13–783)

Gamma-glutamyl transpeptidase (IU/L)

71 (11–990)

Hemoglobin (g/dL)

14.6 (6.5–18.7)

Platelet count (× 104/μL)

21.2 (4.0–47.1)

Triglyceride (mg/dL)

139 (31–1088)

Total cholesterol (mg/dL)

203 (101–370)

High-density lipoprotein cholesterol (mg/dL)

45 (14–86)

Low-density lipoprotein cholesterol (mg/dL)

121 (27–243)

Fasting blood sugar (mg/dL)

103 (65–287)

Glycated hemoglobin (%)

6.0 (4.3–12.6)

Ferritin (ng/mL)

228 (1–2067)

NAFLD fibrosis score

− 1.844 (− 7.060 to 3.394)

Genetic variation (n = 314)

 

 PNPLA3 rs738409, CC/CG/GG/not done

54/129/131/132

 TM6SF2 rs58542926, CC/CT/TT/not done

237/70/7/132

 HSD17B13 rs6834314, AA/AG/GG/not done

161/132/25/128

Histopathological findings (n = 446)

 

 Steatosis, 5%–33%/ 33%–66%/> 66%

164/167/112

 Ballooning, none/few cells/many cells

40/283/120

 Lobular inflammation, no foci/< 2 foci/2–4 foci/> 4 foci per 200 × field

28/254/147/14

 NAFLD activity score, ≤ 2/3,4/≥ 5

35/190/218

 Fibrosis stage, 0/1/2/3/4

51/182/69/110/34

  1. Data are number of patients or median (range) values